Our CEO @SteveChapmanCEO underscores the growing role of renal genetic testing in helping clinicians deliver earlier, more personalized care. When we better understand a patient’s genetic risk, we can intervene sooner and change the course of disease. #ThePowerOfKnowing.

Join our upcoming webinar, An overview of Signatera circulating tumor DNA (ctDNA) monitoring for solid organ transplant, feat. Michael Krainock, MD, PhD, associate medical director of oncology at #Natera. This webinar will explore the potential uses of #MRD monitoring in the

Watch Natera CEO @SteveChapmanCEO on @SquawkCNBC as he shares insights on the molecular residual disease (MRD) landscape and how Signatera is helping transform care for cancer patients.

RT @SquawkCNBC: Genetic testing company $NTRA celebrating 10 years on the Nasdaq. CEO Steve Chapman discusses the company’s latest developm….

RT @NasdaqExchange: 🌿 Precision medicine. 🔬 @NateraGenetics is on a mission to transform the management of disease worldwide through perso….

RT @NasdaqExchange: Welcoming @NateraGenetics to the @NasdaqExchange Opening Bell.

📚🧬Calling all future genetic counselors! #Natera is excited to host the upcoming virtual series featuring our popular Boards trivia, Bayes review, and group study events!. Learn more and register for July sessions today:

Hello from Barcelona! 👋 Speak to our team at booth 15 here at @myESMO Gastrointestinal Cancers Congress 2025! Don't miss our oral abstracts and poster presentations. #ESMOGI25 #Natera.Learn more:

We’re excited to present at #ESMOGI25 - European Society for Medical Oncology Gastrointestinal Cancers Congress. These presentations highlight the continued clinical value of Signatera for molecular residual disease (MRD) assessment across colorectal and rectal cancers, including

RT @ISHLT: Check out this #ISHLTVoices podcast episode, presented by @NateraNeph, on the evolution of #ddcfDNA testing and noninvasive reje….

Join the upcoming AI in Precision Oncology webinar on July 1, sharing recent data on the utility of #MRD testing in management of breast cancer. 🧬. Register today: @liebertpub

🌎 Natera’s 2024 Sustainability Report is now live!.This report reflects the efforts of teams across Natera to help reduce environmental impact, support our communities and foster a culture of belonging, while expanding access to our technology for more patients than ever before.

Join the upcoming AI in Precision Oncology webinar on July 1, sharing recent data on the utility of #MRD testing in management of breast cancer. 🧬. Register today: @liebertpub

Join the upcoming AI in Precision Oncology webinar on July 1, sharing recent data on the utility of #MRD testing in management of breast cancer. 🧬. Register today: @liebertpub

Later this month, Natera celebrates five years since opening lab operations in Austin. In those five years, our Austin team has delivered critical insights that support timely, informed decisions for patients and clinicians around the world. Behind every test is a team of

❤️ One year of progress.❤️ One year of partnership.❤️ One year of Prospera Heart with DQS .Learn more:

Tomorrow! Reserve your spot for the webinar, Illuminating the #CKD patient journey: Clinicogenomic data reshapes research & drug discovery, on June 18! .Register here👉

Today, we celebrate fathers and father figures in all their forms. From guiding hands to quiet support, from hard-earned wisdom to unconditional encouragement, fatherhood shows up in countless ways. Some are dads by biology, others by choice. All leave a lasting impact. To the

RT @CancerNel: Recording our 2nd podcast from #UKOF25 .Steve and Wayne are joined by Dr Francesca Jackson-Spence from @NHSBartsHealth and….

There's still time to reserve your spot for the webinar, Illuminating the #CKD patient journey: Clinicogenomic data reshapes research & drug discovery, on June 18! .Register here👉